Rezera

Rezera is a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3 inflammation pathway. We partnered with 22 Fillmore, a brand consultancy in the Bay Area, to deliver a full corporate rebrand that included a new positioning platform, identity system, campaign development and an overhaul of the company website.